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Abstract
Aim: To evaluate the effect of a novel liquid carrier system of enamel matrix
derivative (Osteogain) soaked on an absorbable collagen sponge (ACS) upon peri-
odontal wound healing/regeneration in furcation defects in monkeys.
Materials and Methods: The stability of the conventional enamel matrix deriva-
tive (Emdogain) and Osteogain adsorbed onto ACS was evaluated by ELISA.
Chronic class III furcation defects were created at teeth 36, 37, 46, 47 in three
monkeys (Macaca fascicularis). The 12 defects were assigned to one of the follow-
ing treatments: (1) open flap debridement (OFD) + ACS, (2) OFD+Emdogain/
ACS, (3) OFD+Osteogain/ACS, and (4) OFD alone. At 16 weeks following
reconstructive surgery, the animals were killed for histological evaluation.
Results: A 20–60% significantly higher amount of total adsorbed amelogenin was
found for ACS-loaded Osteogain when compared to Emdogain. The histomor-
phometric analysis revealed that both approaches (OFD + Emdogain/ACS and
OFD + Osteogain/ACS) resulted in higher amounts of connective tissue attach-
ment and bone formation compared to treatment with OFD + ACS and OFD
alone. Furthermore, OFD + Osteogain/ACS group showed higher new attach-
ment formation, cementum, and new bone area.
Conclusions: Within their limits, the present data indicate that Osteogain pos-
sesses favourable physicochemical properties facilitating adsorption of amelogenin
on ACS and may additionally enhance periodontal wound healing/regeneration
when compared to Emdogain.
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Pre-clinical and clinical studies have
provided substantial evidence on the
biologic potential of an enamel
matrix derivative (EMD) to promote
periodontal wound healing/regenera-
tion and improve the clinical out-
comes in intra-bony, furcation, and
recession-type defects (Miron et al.
2016a). However, due to its fluid
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consistency, the use of EMD gel
(Emdogain) appears to possess lim-
ited space-making potential which,
in defects with a more complicated
anatomy (e.g. so called non-con-
tained-type defects), may not be able
to prevent the collapse of a mucope-
riosteal flap thus limiting the avail-
able space for regeneration
(Mellonig 1999, Lekovic et al. 2000,
Cochran et al. 2003, Shirakata et al.
2007). In order to overcome these
potential shortcomings, clinicians
often combine various types of bone
grafting materials with Emdogain,
especially when treating non-con-
tained-type defects (Sculean et al.
2011). The combination of Emdo-
gain and different types of grafting
materials has been extensively evalu-
ated in pre-clinical and clinical stud-
ies (Lekovic et al. 2000, Cochran
et al. 2003, Shirakata et al. 2007,
Gurinsky et al. 2004, Bokan et al.
2006, Kuru et al. 2006, Yilmaz et al.
2010). Although a recent systematic
review reported that the combination
of Emdogain with bone grafting
materials may lead to statistically
significantly higher clinical improve-
ments, the analysis also revealed a
high heterogeneity between the clini-
cal outcomes obtained with the vari-
ous combination approaches
(Matarasso et al. 2015). One possible
reason for the high clinical variabil-
ity in the outcomes when using the
combination of Emdogain and graft-
ing materials may be related to sub-
stantial differences in enamel matrix
proteins (EMPs) adsorption and sub-
sequent cell proliferation between
the utilized bone grafting materials
(Miron et al. 2015). In this respect,
very recent data from a series of
in vitro studies revealed that the use
of EMD without its propylene-gly-
col-alginate (PGA) carrier markedly
improved protein adsorption when
compared to conventional EMD
(e.g. Emdogain) (Miron et al. 2015).
Further advantages of using EMD
without its PGA carrier is related to
its more fluid consistency and subse-
quent improvement of surface coat-
ing and penetration of EMPs within
the bone biomaterials coupled with
the capacity for a gradual release of
EMPs over time (Miron et al. 2015).
These prominent findings led to the
development of a new liquid carrier
system for EMD (Osteogain) specifi-
cally designed for mixing it with
different biomaterials including bone
grafts and collagen matrices/scaf-
folds. Very recently, Miron et al.
(2016b) reported that pre-coating
Osteogain onto a natural bovine
mineral (NBM) significantly
increased cell adhesion, proliferation,
and differentiation of osteoblasts
in vitro (Miron et al. 2016b) and
improved new bone formation in a
rat femur bone defect model (Zhang
et al. 2016). However, despite these
encouraging data, it is still unclear
to what extent Osteogain is effective
in promoting periodontal wound
healing/regeneration in periodontal
defects.
An important aspect that is still
controversially discussed in the liter-
ature is the need of using bone graft-
ing materials for enhancing
periodontal regeneration. Since most
findings from histological studies in
animals and humans indicate that
the healing following the use of bone
grafting materials is frequently char-
acterized by persistence of grafting
residues embedded either in bone or
encapsulated in connective tissue, the
biologic rationale of using such
materials needs to be questioned
(Ivanovic et al. 2014, Sculean et al.
2015). Thus, although clinical conse-
quences of persisting graft residues
are still unclear, from a biological
point of view, it would be desirable
that a biomaterial used as a carrier
for biologics (e.g. growth factors or
EMD) or to stabilize the wound by
supporting the flap, is completely
resorbed and replaced by regener-
ated periodontal tissues (e.g. cemen-
tum, periodontal ligament, and
bone). During the last decades vari-
ous types of collagens matrices have
been successfully used as carriers for
growth factors and Emdogain, point-
ing to the potential biological advan-
tages of this combination to support
wound healing/regeneration (Susin
et al. 2015, St€ahli et al. 2016).
However, at present, it is
unknown whether the combination
of EMD and an absorbable collagen
sponge (ACS) may represent a
potential option for reconstructive
surgery in complex non-contained
defects such as class III furcation
defects. Therefore, the aim of the
present pre-clinical study was to
evaluate the effects of Osteogain
with ACS in chronic class III furca-
tion defects in non-human primates.
Materials and Methods
Emdogain, Osteogain, and ACSs
Emdogain and Osteogain (0.3 ml
vials, concentration 30 mg/ml; Strau-
mann AG, Basel, Switzerland) and
native type I and III porcine absorb-
able collagen sponges (ACS: Colla-
cone; Botiss, Berlin, Germany)
were utilized in this study.
Quantification of amelogenin adsorption
to ACSs
To determine the quantity of Emdo-
gain/Osteogain adsorption to the sur-
face of ACSs, ELISA quantification
assay was utilized for amelogenin, the
main protein found in EMD encom-
passing 90–95% of the total protein
content. Briefly, 0.3 ml of Emdogain/
Osteogain was poured onto cylindri-
cal ACS scaffolds in six-well dishes
for 10 min at 37C. After the coating
period incubation, the samples were
simply washed with phosphate-buf-
fered saline (PBS), and the remaining
PBS solution containing unattached
enamel matrix proteins was collected
and quantified by a Quantikine
Colorimetric Sandwich ELISA (Por-
cine Amelogenin, X isoform
(AMELX) ELISA Kit; MyBioSource
Inc, San Diego, CA, USA) according
to the manufacturer’s protocol. Sub-
traction of total coated protein from
the amount of unadsorbed protein
was used to determine the amount of
adsorbed material to the surface of
ACS as previously described (Miron
et al. 2015). Furthermore, in order to
determine the quantity of amelogenin
protein being released from ACS over
time, coated ACSs were soaked in
5 ml of PBS and samples were col-
lected at various time points including
15 min, 1 h, 8 h, 1, 3, and 10 days.
All samples were quantified in tripli-
cate and three independent experi-
ments were performed.
Experimental animals
Three 7–8-year old male monkeys
(Macaca fascicularis), weighing 6.91–
7.02 kg, were used. The animals
exhibited intact dentition with healthy
periodontium. They were kept in indi-
vidual cages at 23–29C, relative
humidity of 30–70%, and a 12-hour
light/dark cycle. Approximately,
108 g of solid food (HF Primate J
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12G 5K9J, Purina Mills, LLC, Gray
Summit, MO, USA) was provided to
each animal daily and water was
available ad libitum. All procedures
during the in-life phase for about
9 months (from 6 November 2014 to
3 August 2015) were approved by the
ethical committee of the Animal
Research Center of Kagoshima
University, Japan (approval no.
D14026) and were performed in
accordance with standards published
by the National Research Council
(Guide for the Care and Use of Labo-
ratory Animals, NIH OACU) of the
National Institutes of Health Policy
on Human Care and Use of Labora-
tory Animals.
Preparation of experimental defects
One surgeon (Y. S) performed all sur-
gical procedures under general and
local anaesthesia using aseptic rou-
tines. Before the operation, buprenor-
phine hydrochloride (Lepetan injection
0.2 mg; Otsuka Pharmaceutical Co.,
Ltd, Tokyo, Japan, 0.1 ml/Kg), to
ameliorate pain, and an antibiotic
(Mycilinzol Meiji, 0.05 ml/kg; Meiji
Seika Pharma Co., Ltd, Tokyo,
Japan), to prevent infection, were
administered intramuscularly. General
anaesthesia was achieved with a keta-
mine hydrochloride (0.2 ml/kg IM;
Supriya Lifescience Ltd, Mumbai,
India)/medetomidine hydrochloride
(Domitor, 0.08 ml/kg IM; Orion Cor-
poration, Espoo, Finland) combina-
tion maintaining spontaneous
breathing. Local anaesthesia was per-
formed using lidocaine HCl/epinephr-
ine (2%, 1:80,000; Xylocaine, Fujisawa
Inc., Osaka, Japan). After the opera-
tion, atipamezole hydrochloride (Anti-
sedan, 0.08 ml/kg, Orion Corporation)
was administered intramuscularly.
Ketoprofen (Capisten IM 50 mg,
2 mg/kg, 0.1 ml/kg; Kissei Pharma-
ceutical Co., Ltd, Matsumoto, Japan),
to ameliorate pain, and an antibiotic
(Mycilinzol Meiji, 0.05 ml/kg; Meiji
Seika Pharma Co., Ltd), to prevent
infection, were intramuscularly admin-
istered to all animals for 2 days after
operation.
As a pre-treatment, the second
premolars and third molars in the
mandible were extracted for flap man-
agement to prevent material exposure
and obtain primary closure as previ-
ously described (Donos et al.2003,
Gkranias et al. 2012). After a healing
period of 2 months, the mucope-
riosteal flaps were raised and class III
furcation defects were surgically cre-
ated at the first and the second
mandibular molars with the use of
bone chisels and slowly rotating dia-
mond burs (12 defects in total). The
dimensions of the exposed furcation
defects were 5 mm wide and 5 mm
high. In order to prevent spontaneous
healing and induce plaque accumula-
tion, the defects were filled with
impression materials (EXAFINE
PUTTY TYPE, GC Corporation,
Tokyo, Japan) (Fig. 1a). Subse-
quently, the flaps were repositioned
and stabilized with 4-0 silk sutures
(MersilkTM; Ethicon Ltd, Edinburgh,
UK). Sutures were removed at
10 days following surgery. During
8 weeks following the first surgery,
no oral hygiene measures were per-
formed and the animals were fed a
soft diet. After 8 weeks, the impres-
sion material was removed from the
defects and a plaque control regimen,
consisting of oral cavity flushing with
a chlorhexidine gluconate solution
(5% HIBITANE, 25 ml of a 2%
solution; Sumitomo Dainippon
Pharma Co., Ltd., Osaka, Japan) was
performed for a period of 4 weeks.
Reconstructive surgery
At 16 weeks following creation of the
defects (Fig. 1b), intra-sulcular inci-
sions were performed and full-thick-
ness buccal and lingual flaps were
elevated in order to expose the furca-
tion defects. All granulation tissue
(Fig. 1c) was removed and the
exposed root surface was carefully
scaled and planed. Cementum was
removed using Gracey curettes and a
chisel (Fig. 1d). Reference notches
were made using a #1 round bur on
the root surface at the base of the
defects for histometric analysis. Class
III furcation defects received one of
the following treatments: ACS alone,
Emdogain with ACS (Emdogain/
ACS), Osteogain with ACS (Osteo-
gain/ACS), and open flap debride-
ment (OFD) as a surgical control.
The experimental conditions were
rotated between defect sites in subse-
quent animals. Emdogain/ACS and
Osteogain/ACS were not placed in
the same unilateral side in the same
animal. In the ACS group, ACS was
mixed with sterile saline before being
applied to the defect. Root surfaces
that received Emdogain or Osteogain
were conditioned with a 24% EDTA
gel (PrefGel; Straumann AG) for
2 min and then, along with the adja-
cent mucoperiosteal flaps, thoroughly
rinsed with sterile saline. Prior to the
placement of Emdogain/ACS or
Osteogain/ACS, the ACS was fully
saturated with Emdogain or Osteo-
gain and the constructs were allowed
to rest for 10 min (Fig. 1e). The con-
structs were then filled in the defect
with moderate pressure (Fig. 1f).
Maximum care was taken during sur-
gery to prevent mixing of Emdogain
or Osteogain to the other site in the
same side of the mandible.
A periosteal releasing incision was
made to allow coronal displacement
of the flap, followed by suturing
(Gore-Tex CV-6 Suture; W.L. Gore
& Associates Inc., Flagstaff, AZ,
USA) slightly coronal to the CEJ
(Fig. 1g). After reconstructive sur-
gery, the animals received similar
treatments of the antibiotics and anal-
gesics which were used during prepa-
ration of experimental defects.
Sutures were removed after 14 days
of healing and postoperative plaque
control was maintained as previously
described. Then, 4 months after the
reconstructive surgery (Fig. 1h) the
animals were anesthetized by an
intravenous injection of sodium pen-
tobarbital (64.8 mg/ml, 0.4 ml/kg;
Tokyo Chemical Industry Co., Ltd,
Tokyo, Japan) and killed by exsan-
guination.
Histological processing
All the defects, including the experi-
mental and control sites, were then
dissected with the surrounding soft
and hard tissues. The tissue blocks
were fixed in 10% buffered formalin,
trimmed, and rinsed in PBS. The
samples were decalcified in Kalki-
toxTM solution (Wako Pure Chemical
Industries Ltd., Osaka, Japan) for
3 weeks, dehydrated, and embedded
in paraffin. Step serial sections of
6 lm thickness were then prepared
along the mesio-distal plane, stained
with haematoxylin/eosin or with
Azan–Mallory at intervals of 90 lm.
Histometric analysis
All the specimens were analysed his-
tometrically under a light microscope
(Eclipse E800; Nikon Inc., Tokyo,
© 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
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Japan) equipped with a computerized
imaging system (Image-pro Plus
Media Cybernetics, Silver Spring,
MD, USA). For the histometric anal-
ysis, three sections approximately
90 lm apart were selected from the
most central area of each class III
furcation defect, identified by the
length of the root canal and the refer-
ence notches. A line connecting both
notches defined the apical limit of the
defect and the following parameters
were measured by the same experi-
enced and masked examiner (T. N.).
The mean value of each histometric
parameter was then calculated for
each site.
Area measurements (in mm2 and %)
1 Bone defect area (BDA): area lim-
ited by the apical line and the root
surface in the furcation region;
2 Non-filled area (NFA): portion of
the BDA not filled with any tissue,
partially filled with plaque depos-
ited on the root surface;
3 Epithelium tissue area (ETA): por-
tion of the BDA filled with epithe-
lium tissue;
4 Connective tissue area (CTA):
portion of the BDA filled with
connective tissue;
5 New bone area (NBA): portion of
the BDA filled with new bone
Area measurements, except for
BDA, were calculated as the percent-
age of the BDA within each defect.
Linear measurements (in mm and %)
1 Length of the root surface (LRS):
length of the root surface from the
mesial notch to the distal notch;
2 Tissue-free defect length (TFL):
portion of the LRS with the absence
of any new tissue formation;
3 Junctional epithelial migration
(JE): total linear extensions of the
root surface covered by epithelial
tissue;
4 Connective tissue adhesion (CT):
total linear extensions of the root
surface covered by connective tis-
sue without cementum;
5 New cementum formation (NC):
total linear extensions of the root
surface coved by new cementum:
6 New attachment formation (NA):
total linear extensions of the root
surface covered by NC adjacent to
newly formed bone, with function-
ally oriented collagen fibres
Linear measurements, except for
LRS, were also expressed as the per-
centage of the LRS within each defect.
Examiner calibration
Thirty-six sections from all sites were
read by the examiner without cali-
bration before the measurements.
(a) (b)
(c) (d)
(e) (f)
(g) (h)
Fig. 1. Clinical appearance of the mandibular buccal aspect of Macaca fascicularis. (a)
Induction of chronic inflammation. After fabrication of Class III furcation defects,
impression materials were placed to encourage growth of oral microflora along the
exposed root surfaces. (b) Prior to reconstructive surgery. (c) Immediately after flap
reflection. Note the excessive granulation tissue in the chronic defects. (d) Defects were
exposed and debrided again at the time of reconstructive surgery. (e) Osteogain/ab-
sorbable collagen sponge (ACS) construct before surgical implantation. (f) left (second
molar): ACS alone, right (first molar): placement of Osteogain/ACS. (g) Flaps were
coronally repositioned and sutured. (h) 16 weeks after reconstructive surgery.
© 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
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Forty-eight hours later, the same
examiner read all 36 sections again
to evaluate intra-examiner repro-
ducibility. Inter-calibration of the
examiner was accepted at the 90%
level. Because of low sample size due
to the selected model chosen, the sta-
tistical analysis was restricted to
descriptive statistics.
Statistical analysis
For the amelogenin ELISA quantifi-
cation experiments, means and stan-
dard errors (SE) were calculated.
Statistically significant differences
were examined by multiple t-tests
between both groups. Statistical sig-
nificance was defined as a p-value of
0.05 corrected using the Bonferroni–
Dunn method utilizing GraphPad
Prism software (La Jolla, CA, USA).
Results
Ability to adsorb and release Emdogain
and Osteogain over time
ELISA was utilized to investigate
the amount of adsorbed amelogenin
when Emdogain or Osteogain were
loaded onto ACS (Fig. 2). While it
was first found that both carriers
efficiently loaded amelogenin onto
the collagen sponges at time point 0,
a simple saline rinse with PBS signif-
icantly removed over 20% more
(from >90% to 70%) of the total
amelogenin content from Emdogain
when compared to Osteogain where
the total protein content remained
<90% of the initial concentrations
(Fig. 2). At each of the remaining
time points thereafter, a 20–60% sig-
nificantly higher amount of total
adsorbed amelogenin was found for
collagen sponges loaded with Osteo-
gain when compared to Emdogain
(Fig. 2). After a 10-day period,
nearly 60% of the initial amelogenin
protein content found in Osteogain
remained present within the collagen
sponges, whereas in the Emdogain
samples, no remaining amelogenin
could be quantified as values
approached 0% (Fig. 2).
Clinical observations
All surgical treatments were well tol-
erated by the animals, and clinical
healing was uneventful at all 12 sites.
No visible adverse reactions includ-
ing material exposure, infection, and
suppuration were observed through-
out the experimental period.
Histological observations
OFD group
In the OFD group, apical migration
of the junctional epithelium consid-
erably occurred (Fig. 3a,e,i) with
varying degrees of new attachment,
and new bone formation was
observed. In one defect, considerable
new cementum formation and mod-
erate new attachment formation
occurred (Fig. 3a). Artefacts (separa-
tions between the new cementum
and the root surface) were consis-
tently detected in all three defects.
Thick new cellular cementum with
or without collagen fibres obliquely
oriented to the root surface was seen
in the lower portion of the defect
(Fig. 4a,b). The collagen fibres
appeared to be sparser than those
observed in the Emdogain/ACS and
Osteogain/ACS groups (Figs 3e,i
and 4b).
ACS group
The healing pattern in the ACS
group was characterized by limited
periodontal regeneration (Fig. 3b, f
and j). Junctional epithelium
migrated to the most coronal exten-
sion of new cementum with less con-
nective tissue adhesion (Fig. 4c,d). A
small amount of new bone formed
in the lower portion of the defect
(Fig. 3b,f,j). New cementum forma-
tion and new attachment formation
were minimal in one defect, and
restricted to the mid portion of the
rest of two defects. Moderate thick
and thin cellular cementum with or
without collagen fibres obliquely ori-
ented to the root surface was
observed (Fig. 4c,d).
Emdogain/ACS group
In the Emdogain/ACS group, apical
extension of the junctional epithe-
lium was more restrained than in the
OFD and ACS groups. A greater
amount of new cementum was
observed in the EMD group than in
the control and ACS groups. New
bone formation was noted extending
from the apical notch towards the
coronal region of the defect (Fig. 3g,
k). Thin acellular cementum and
thick cellular cementum, with colla-
gen fibres obliquely oriented to the
root surfaces, were observed
(Fig. 4e,f). Furthermore, the collagen
fibres appeared to be denser than
those observed in the OFD and ACS
groups. Many blood vessels were
observed within the newly formed
periodontal ligament (Fig. 4e,f).
Osteogain/ACS group
In general, the healing pattern in the
Osteogain/ACS group was similar to
the Emdogain/ACS group. However,
migration of junctional epithelium
was more restrained in the Osteo-
gain/ACS group than in the OFD,
ACS, and Emdogain/ACS groups.
Furthermore, new attachment and
new bone formation were consis-
tently noted extending from the
apical notches towards the coronal
region of the defect in all defects
(Fig. 3d,h, l). Moderately thick new
cellular and thin acellular cemen-
tum, with dense collagen fibres
obliquely or perpendicular oriented
to the denuded root surface was
more consistently observed (Fig. 4g,
h). Highly vascularized new peri-
odontal ligament-like tissue, tightly
confined to between the new cemen-
tum and new bone, maintained its
width up to the coronal portion
(Fig. 4g,h).
Fig. 2. In vitro release profiles of Emdogain and Osteogain from absorbable collagen
sponge. (*, p values < 0.05 was considered significant).
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ACS appeared to be completely
resorbed after 16 weeks of healing in
the ACS, Emdogain/ACS, and
Osteogain/ACS groups. Complete
defect resolution of furcation defects
was not achieved in any of defects
in all four treatment groups. There
was neither extensive root resorption
nor ankylosis, irrespective of the
experimental group.
Histometric analysis
The results of histometric analysis are
summarized in Tables 1 and 2. The
ETA/BDA in the Emdogain/ACS
(14.6  2.7%) and Osteogain/ACS
(14.3  1.5%) groups were lower
than those in the OFD (19.2  3.9%)
and ACS (21.7  3.2%) groups.
Osteogain/ACS group showed the
greatest amount of newly formed
bone (NBA/BDA) among the groups
examined. The length of junctional
epithelium migration observed in the
Osteogain/ACS group was shorter
than those in the OFD, ACS, and
Emdogain/ACS groups. The Emdo-
gain/ACS and Osteogain/ACS groups
showed greater cementum formation
than the ACS group. The amount of
(a) (b) (c) (d)
(e) (f) (g) (h)
(i) (j) (k) (l)
Fig. 3. Overview photomicrographs of all Class III furcation defects in different groups (Azan-Mallory staining). (a), (e), and (i):
Open flap debridement (OFD) group Overview. (scale bar: 1 mm). (b), (f), and (j): Absorbable collagen sponge (ACS) group Over-
view. (scale bar: 1 mm). (c), (g), and (k): Emdogain/ACS group Overview. (scale bar: 1 mm). (d), (h), and (l): Osteogain/ACS group
Overview. (scale bar: 1 mm). Arrowhead: notch (apical extent of root planing).
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new cementum in the Osteogain/ACS
group (40.5  7.2%) was twice as
great as in the ACS group (19.4 
7.5%). Moreover, new attachment
formation was most extensive in the
Osteogain/ACS (37.4  4.6%) group
when compared to the OFD
(19.4  6.9%), ACS (14.1  9.6%),
and Emdogain/ACS (25.0  1.8%)
groups.
Discussion
To the best of our knowledge, this
is the first report evaluating the
potential effects on periodontal
wound healing/regeneration of a
new liquid carrier system for EMD
(Osteogain) in chronic class III fur-
cation defects in non-human pri-
mates. Many investigators have
become interested in the plausible
reasons for the high clinical variabil-
ity for studies reporting the combi-
nation of EMD with bone grafting
materials (Tu et al. 2010, Miron
et al. 2014). Previous data have
shown that the use of Emdogain,
although ideal for root surface
adsorption, displayed drastically
increased thickness of coating to the
bone grating surface which was
easily dissolved following a simple
PBS rinse. Contrarily, the use of
Osteogain (EMD dissolved in
acetic acid solution) exhibited more
favourable surface coating by
demonstrating an increase and more
complete surface loading of porous
graft materials and tighter and more
stable surface coatings with enamel
matrix proteins (Miron et al. 2015).
In this study, we used ACS as a
putative carrier for EMD since ACS
has been extensively used as an
appropriate carrier including high
clinical applicability, biocompatibil-
ity, and uneventful biodegradation in
bone and periodontal surgeries
(McPherson 1992, Cochran et al.
2000, Yamashita et al. 2010, Kim
et al. 2013). In addition, it has been
reported that the fast resorption of a
residual material is desirable to avoid
the risk for infection and to increase
the amount of regenerated tissues in
bone/periodontal defects (MacNeill
et al. 1999, Shirakata et al. 2002,
2007, Potijanyakul et al. 2010, Yosh-
inuma et al. 2012). Histological find-
ings demonstrated that ACS was
completely resorbed after 16 weeks of
healing in the ACS, Emdogain/ACS,
(a) (b) (c) (d)
(e) (f) (g) (h)
Fig. 4. Representative photomicrographs of Class III furcation defects in open flap debridement (OFD) group (Azan-Mallory stain-
ing). (a) Higher magnification of the framed area (left) in Fig. 3i (scale bar: 200 lm), (b) Higher magnification of the framed area
(right) in Fig. 3i (scale bar: 200 lm), in ACS group (c) Higher magnification of the framed area (left) in Fig. 3f (scale bar: 200 lm),
(d) Higher magnification of the framed area (right) in Fig. 3f (scale bar: 200 lm), in Emdogain/ACS group (e) Higher magnification
of the apical framed area (left) in Fig. 3g, (f) Higher magnification of the framed area (right) in Fig. 3g (scale bar: 200 lm), and in
Osteogain/ACS group (g) Higher magnification of the framed area (left) in Fig. 3d (scale bar: 200 lm), (h) Higher magnification of
the framed area (right) in Fig. 3d (scale bar: 200 lm). JE: junctional epithelium, NB: new bone, D: root dentin, NC: new cemen-
tum, PDL: periodontal ligament.
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and Osteogain/ACS groups. Com-
plete resolution of all furcation
defects was not achieved in any of the
specimens. On the one hand, the
incomplete regeneration may be
explained by the large chronic-type,
furcation defects exhibiting a lower
healing potential and by the difficul-
ties to ensure a plaque-free healing
environment in this animal model
(Caton et al. 1994, Donos et al.
2003). It has been extensively
demonstrated that periodontal
wound healing and the outcomes fol-
lowing conventional and regenerative
periodontal surgery are negatively
influenced by plaque accumulation of
the wound area (Rosling et al. 1976,
Table 1. Histomorphometric area measurement in each group (mean  SD in mm2 and %; n = 3 animals, n = 12 sites)
Histometric parameter Animal No Experimental condition
Control ACS Emdogain/ACS Osteogain/ACS
BDA (mm2) 1 12.3 11 16.2 12.7
2 13.1 10.2 11.6 14.5
3 12.1 18 11.6 17.5
Mean  SD 12.5  0.5 13.1  4.3 13.1  2.7 15.0  2.4
NFA in mm2 and (%) 1 0 (0.4) 2.7 (25.0) 4.9 (30.3) 3.2 (25.6)
2 5.9 (45.4) 3.1 (30.5) 3.4 (28.8) 2.6 (17.7)
3 1.5 (12.4) 5.2 (28.6) 1.1 (9.5) 4.2 (24.3)
Mean  SD 2.5  3.1 (19.4  23.4) 3.7  1.3 (28.0  2.8) 3.1  1.9 (22.9  11.6) 3.4  0.8 (22.5  4.3)
ETA in mm2 and (%) 1 2.5 (20.5) 2.6 (23.8) 2.4 (14.7) 1.6 (13.0)
2 1.9 (14.8) 1.8 (17.9) 1.4 (11.9) 2.1 (14.1)
3 2.7 (22.4) 4.2 (23.3) 2.0 (17.2) 2.8 (15.9)
Mean  SD 2.4  0.4 (19.2  3.9) 2.9  1.2 (21.7  3.2) 1.9  0.5 (14.6  2.7) 2.2  0.6 (14.3  1.5)
CTA in mm2 and (%) 1 2.0 (16.7) 1.4 (13.1) 2.4 (14.7) 1.2 (9.5)
2 1.3 (9.6) 1.9 (18.4) 1.4 (11.9) 1.8 (12.1)
3 2.4 (20.1) 3.8 (21.0) 2.9 (25.3) 3.2 (18.2)
Mean  SD 1.9  0.6 (15.4  5.4) 2.4  1.2 (17.5  4.0) 2.2  0.8 (17.3  7.1) 2.1  1.0 (13.3  4.5)
NBA in mm2 and (%) 1 3.2 (26.3) 3.8 (34.5) 5.4 (33.4) 5.4 (42.4)
2 3.2 (24.1) 2.8 (27.1) 4.3 (37.0) 6.9 (47.2)
3 4.1 (34.3) 3.1 (17.2) 3.6 (30.9) 5.3 (30.2)
Mean  SD 3.5  0.6 (28.3  5.3) 3.2  0.5 (26.3  8.7) 4.4  0.9 (33.8  3.0) 5.8  0.9 (39.9  8.8)
ACS, absorbable collagen sponge; BDA, bone defect area; NFA, non-filled area; ETA; epithelium tissue area; CTA, connective tissue area;
NBA, new bone area.
Table 2. Histomorphometric linear measurement in each group (mean  SD in mm and %; n = 3 animals, n = 12 sites)
Histometric parameter Animal No Experimental condition
Control ACS Emdogain/ACS Osteogain/ACS
LRS (mm) 1 12.3 10.1 13.1 12
2 11.3 10.7 11.7 12.3
3 12.2 14.5 10.9 16.5
Mean  SD 11.9  0.5 11.8  2.4 11.9  1.1 13.6  2.5
TFL in mm and (%) 1 1.4 (11.6) 5.8 (57.2) 7.0 (53.8) 5.4 (44.6)
2 7.9 (69.8) 5.5 (51.7) 5.7 (48.6) 5.5 (45.1)
3 3.8 (31.0) 7.3 (50.5) 4.6 (42.2) 7.3 (44.3)
Mean  SD 4.4  3.3 (37.5  29.6) 6.2  1.0 (53.1  3.6) 5.8  1.2 (48.2  5.8) 6.1  1.1 (44.7  0.4)
JE in mm and (%) 1 6.2 (50.7) 2.0 (19.9) 1.6 (11.9) 1.5 (12.5)
2 0.9 (7.6) 2.7 (25.4) 1.6 (14.1) 1.5 (12.5)
3 5.0 (40.6) 4.9 (33.9) 3.7 (33.9) 3.6 (22.0)
Mean  SD 4.0  2.8 (33.0  22.5) 3.2  1.5 (26.4  7.0) 2.3  1.2 (19.9  12.1) 2.2  1.2 (15.7  5.5)
CT in mm and (%) 1 0.4 (2.9) 0 (0) 0.2 (1.1) 0.1 (1.1)
2 0.1 (0.4) 0.3 (2.5) 0.6 (5.5) 0.2 (1.6)
3 0.1 (1.2) 0.1 (0.7) 0.3 (2.8) 0.4 (2.4)
Mean  SD 0.2  0.2 (1.5  1.3) 0.1  0.1 (1.1  1.3) 0.4  0.3 (3.1  2.2) 0.2  0.1 (1.7  0.7)
NC in mm and (%) 1 5.1 (41.6) 2.8 (27.3) 3.9 (29.9) 5.0 (41.3)
2 2.6 (23.1) 2.0 (18.5) 3.8 (32.6) 5.8 (47.2)
3 3.3 (26.9) 1.8 (12.4) 4.3 (39.7) 5.4 (32.9)
Mean  SD 3.7  1.3 (30.5  9.8) 2.2  0.5 (19.4  7.5) 4.0  0.3 (34.1  5.1) 5.4  0.4 (40.5  7.2)
NA in mm and (%) 1 3.3 (26.9) 2.4 (23.4) 3.0 (23.1) 4.9 (40.8)
2 2.1 (18.1) 1.6 (14.7) 3.1 (26.6) 4.8 (39.2)
3 1.6 (13.2) 0.6 (4.2) 2.8 (25.4) 5.3 (32.3)
Mean  SD 2.3  0.9 (19.4  6.9) 1.5  0.9 (14.1  9.6) 3.0  0.2 (25.0  1.8) 5.0  0.3 (37.4  4.6)
ACS, absorbable collagen sponge; LRS, length of the root surface; TFL, tissue-free defect length, JE, junctional epithelial migration; CT,
connective tissue adhesion; NC, new cementum; NA, new attachment formation.
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Nyman et al. 1977, Lindhe et al.
1995, Tonetti et al. 1996, Rossa et al.
2000, Gkranias et al. 2012). On the
other hand, it cannot be excluded
that the used ACS did not possess the
optimal mechanical characteristics to
ensure sufficient stability of the
wound, subsequently resulting in a
collapse of the mucoperiosteal flap
and more limited space for regenera-
tion (Susin et al. 2015). Although the
expenses and demanding mainte-
nance may restrict the broad use of
non-human primates, the microbio-
logical, immunological, and morpho-
logical features are quite similar to
those of humans (Pellegrini et al.
2009). Furthermore, chronic peri-
odontal defects with minimal sponta-
neous repair are valuable for
evaluating new medical formulations
or drugs as a putative periodontal
regenerative therapy prior to clinical
application in humans (Caton et al.
1994, Giannobile et al. 1994). The
amount of new tissue formation
obtained in the Emdogain/ACS and
Osteogain/ACS groups was greater
than those in the OFD and ACS
groups in the present animal model.
Furthermore, the migration of the
junctional epithelium was more
restricted in the Emdogain/ACS and
Osteogain/ACS groups compared to
the OFD and ACS groups. For the
newly formed cementum, no distinct
qualitative differences were observed
between the Emdogain/ACS and the
Osteogain/ACS group, they were
composed of mixed cellular/acellular
cementum (Araujo & Lindhe 1998,
Donos et al. 2003, Shirakata et al.
2007, Gkranias et al. 2012). Func-
tionally oriented collagen fibres with
many blood vessels in some parts
along the denuded root surface were
observed, and they appeared to be
denser than those observed in the
control and ACS groups. These find-
ings are comparable to those of previ-
ous studies reporting that EMD
histologically presented positive
regeneration results in animals and
human biopsies (Hammarstr€om et al.
1997, Heijl et al. 1997, Mellonig
1999, Donos et al. 2003, Hovey et al.
2006, Shirakata et al. 2007, Gkranias
et al. 2012, Ivanovic et al. 2014, Scu-
lean et al. 2015).
Interestingly, the amount of the
regenerated tissue (i.e. NBA, NC, and
NA) was the greatest in the Osteo-
gain/ACS group, superior to that
obtained in the Emdogain/ACS
group. This may be due to the fact
that the ELISA assay demonstrated
that a 20–60% significantly higher
amount of total adsorbed amelogenin
was found for the Osteogain/ACS
group when compared to Emdogain/
ACS. Furthermore, the ACS loaded
with Emdogain started to degrade in
PBS by 3 days, whereas those pre-
coated with Osteogain showed more
stable properties. These findings sug-
gest that Osteogain-adsorbed ACS
not only maintains the sustained
release of amelogenin but also pro-
vides an environment conducive to
accelerating periodontal regeneration.
Furthermore, the positive effects of
Osteogain on periodontal regenera-
tion may be explained by previous
findings indicating that Osteogain sig-
nificantly increased cell adhesion,
proliferation, and differentiation of
osteoblasts in vitro (Miron et al.
2016b), as well as promoted the upre-
gulation of genes encoding BMP-2,
TGF-b1, collagen 1 and osteocalcin
(Miron et al. 2016c).
Within their limits, the present
data indicate that Osteogain pos-
sesses favourable physicochemical
properties facilitating adsorption of
amelogenin on ACS and may addi-
tionally enhance periodontal wound
healing/regeneration when compared
to Emdogain. None of the treat-
ments achieved complete regenera-
tion, that is, class III furcation still
persisted after treatment. Further
pre-clinical and clinical studies are
thus warranted to evaluate the bio-
logic and clinical value of this novel
EMD formulation on periodontal
wound healing/regeneration.
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Clinical Relevance
Scientific rationale for the study: A
new liquid carrier system for
enamel matrix derivative (EMD)
(Osteogain) has recently been
developed to facilitate bone bioma-
terial mixing. This study evaluated
the effect of Osteogain with
absorbable collagen sponges (ACS)
in chronic class III furcation defects
in monkeys.
Principal findings: Statistically signifi-
cantly higher amount of total
adsorbed amelogenin was detected
for Osteogain/ACS when compared
to Emdogain, which yielded higher
amounts of new connective tissue
attachment and bone formation in
furcation defects.
Practical implications: Osteogain/
ACS promoted periodontal wound
healing/regeneration in class III
furcation defects, thus warranting
further evaluation in preclinical
and clinical settings.
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